Currently out of the existing stock ratings of Francois Brisebois, 122 are a BUY (94.57%), 7 are a HOLD (5.43%).

Francois Brisebois

Work Performance Price Targets & Ratings Chart

Analyst Francois Brisebois, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 26.67% that have a potential upside of 36.2% achieved within 138 days.

Francois Brisebois’s has documented 247 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AQST, Aquestive Therapeutics at 02-Jun-2025.

Wall Street Analyst Francois Brisebois

Analyst best performing recommendations are on DMTK (DERMTECH).
The best stock recommendation documented was for DMTK (DERMTECH) at 1/22/2021. The price target of $53 was fulfilled within 14 days with a profit of $10.08 (23.49%) receiving and performance score of 16.78.

Average potential price target upside

of $28.05 (71.74%) on PCSA (PROCESSA PHARMACEUTICALS).
of $26.19 (157.16%) on TARS (TARSUS PHARMACEUTICALS ).
of $22.33 (116.53%) on DYN (DYNE THERAPEUTICS ).

AVDL Avadel Pharmaceuticals PLC DRRX Durect FLXN Flexion Therapeutics HRMY Harmony Biosciences Holdings ICAD icad inc KALA Kala Pharmaceuticals ACHV Achieve Life Sciences AQST Aquestive Therapeutics CMPS Compass Pathways Plc DMTK DermTech ICPT Intercept Pharmaceuticals OTIC Otonomy CYBN Cybin DMAC DiaMedica Therapeutics PCSA Processa Pharmaceuticals TARS Tarsus Pharmaceuticals SLP Simulations Plus MDWD Mediwound Ltd MNMD Mind Medicine BNGO Bionano Genomics DYN Dyne Therapeutics MDXH MDxHealth SA ADR SERA Sera Prognostics SVRA Savara CNTA Centessa Pharmaceuticals PLC ADR PRAX Praxis Precision Medicines TRDA Entrada Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ami Fadia (NEEDHAM)